AOLS (Aeolus Pharmaceuticals) ROCE %: -569.12% (As of Jun. 2017)


What is Aeolus Pharmaceuticals ROCE %?

Aeolus Pharmaceuticals AOLS ROCE % is -569.12% as of Jun. 2017.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aeolus Pharmaceuticals's annualized ROCE % for the quarter that ended in Jun. 2017 was -569.12%.

Aeolus Pharmaceuticals  (OTCPK:AOLS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aeolus Pharmaceuticals ROCE % Related Terms

Aeolus Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals ROCE % Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -6.99 -709.73 -278.55

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.75 -110.89 -163.15 -253.83 -569.12

Aeolus Pharmaceuticals ROCE % Calculation

Aeolus Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Sep. 2016 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2016 )  (A: Sep. 2015 )(A: Sep. 2016 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2016 )  (A: Sep. 2015 )(A: Sep. 2016 )
=-3.273/( ( (1.777 - 2.622) + (4.167 - 0.972) )/ 2 )
=-3.273/( (-0.845+3.195)/ 2 )
=-3.273/1.175
=-278.55 %

Aeolus Pharmaceuticals's ROCE % of for the quarter that ended in Jun. 2017 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2017 )  (Q: Mar. 2017 )(Q: Jun. 2017 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2017 )  (Q: Mar. 2017 )(Q: Jun. 2017 )
=-3.796/( ( (1.765 - 0.638) + (0.794 - 0.587) )/ 2 )
=-3.796/( ( 1.127 + 0.207 )/ 2 )
=-3.796/0.667
=-569.12 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2017) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -569.12% mean?
Aeolus Pharmaceuticals (AOLS) has a ROCE % of -569.12% as of Jun. 2017.
Is Aeolus Pharmaceuticals' ROCE % too high?
Aeolus Pharmaceuticals' current ROCE % is -569.12%.
How does Aeolus Pharmaceuticals' ROCE % compare to RDGL and PCYN?
Aeolus Pharmaceuticals' ROCE % of -569.12% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aeolus Pharmaceuticals's current ROCE % is -569.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current ROCE % of -569.12%. The current ROCE % is -569.12%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current ROCE % is -569.12% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.